RSS-Feed abonnieren
DOI: 10.1055/s-2005-871575
A Review of Advances in the Synthesis of Analogues of the Delphinium Alkaloid Methyllycaconitine
Publikationsverlauf
Publikationsdatum:
22. Juni 2005 (online)
Abstract
Neuronal nicotinic acetylcholine receptors of the α7 sub-type are potential targets for drug development in the treatment of Alzheimer’s disease. The Delphinium alkaloid methyllycaconitine is a potent and selective α7 sub-type selective nicotinic acetylcholine receptor antagonist. The total synthesis of this pharmacologically active alkaloid has not yet been achieved. A summary of semi-synthetic methods to prepare methyllycaconitine is presented. Existing synthetic strategies used to prepare E, AE, AEF, ABE, ABDE, ABEF ring analogues of methyllycaconitine are reviewed for the first time.
-
1 Introduction
-
1.1 Alzheimer’s Disease and α7 Nicotinic Acetylcholine Receptors
-
1.2 Methyllycaconitine - An α7 Subtype Selective Nicotinic Acetylcholine Receptor Antagonist
-
1.3 Structure-Activity Relationships of Delphinium Alkaloids
-
2 Semi-Syntheses of Delphinium Alkaloids
-
3 Synthesis of Analogues of Methyllycaconitine
-
3.1 Synthesis of E Ring Analogues of Methyllycaconitine
-
3.2 Synthesis of AE Ring Bicyclic Analogues of Methyllycaconitine
-
3.3 Synthesis of AEF Ring Tricyclic Analogues of Methyllycaconitine
-
3.4 Synthesis of ABE Ring Tricyclic Analogues of Methyllycaconitine
-
3.5 Synthesis of ABDE Ring Tetracyclic Analogues of Methyllycaconitine
-
3.6 Synthesis of ABEF Ring Tetracyclic Analogues of Methyllycaconitine
-
4 Conclusion
Key words
semi-synthesis - Delphinium alkaloids - nicotinic acetylcholine receptor α7 sub-type selective antagonists
- 1
Cooper JR.Bloom FE.Roth RH. The Biochemical Basis of Neuropharmacology 8th ed.: Oxford University Press; Oxford: 2003. - 2
Levin ED.Rezvani AH. Eur. J. Pharmacol. 2000, 393: 141 - 3
Hellstrom-Lindahl E. Eur. J. Pharmacol. 2000, 393: 255 - 4
Marx J. Science 1996, 273: 50 - 5
Papke RL.Meyer E.Nutter T.Uteshev VV. Eur. J. Pharmacol. 2000, 393: 179 - 6
Pereira EFR.Hilmas C.Santos MD.Alkondon M.Maelicke A.Albuquerque EX. J. Neurobiol. 2002, 53: 479 - 7
Levin ED.Bradley A.Addy N.Sigurani N. Neuroscience 2002, 109: 757 - 8
Clementi F.Fornasari D.Gotti C. Eur. J. Pharmacol. 2000, 393: 3 - 9
Holladay MW.Dart MJ.Lynch JK. J. Med. Chem. 1997, 40: 4169 - 10
Martin-Ruiz CM.Court JA.Molnar E.Lee M.Gotti C.Mamalaki A.Tsouloufis T.Tzartos S.Ballard C.Perry RH.Perry EK. J. Neurochem. 1999, 73: 1635 - 11
Addy NA.Nakijama A.Levin ED. Cogn. Brain Res. 2003, 16: 51 - 12
Wang H.Lee DHS.Davis CB.Shank RP. J. Neurochem. 2000, 75: 1155 - 13
Perry E.Martin-Ruiz C.Lee M.Griffiths M.Johnson M.Piggot M.Haroutunian V.Buxbaum JD.Nasland J.Davis K.Gotti C.Clementi F.Tzartos S.Cohen O.Soreq H.Jaros E.Perry R.Ballard C.McKeith I.Court J. Eur. J. Pharmacol. 2000, 393: 215 - 14
Selkoe DJ. Trends Cell. Biol. 1998, 8: 447 - 15
Pettit DL.Shao Z.Yakel JL. J. Neurosci. 2001, 21: RC120 - 16
Dougherty JJ.Wu J.Nichols RA. J. Neurosci. 2003, 23: 6740 - 17
Sharples CGV.Wonnacott S. Tocris Reviews 2001, 19: 1 - 18
Dinley KT.Westerman M.Bui D.Bell K.Ashe KH.Sweatt JD. J. Neurosci. 2001, 21: 4125 - 19
Whiteaker P.Marks MJ.Grady SR.Lu Y.Picciotto MR.Changeux J.Collins AC. Eur. J. Pharmacol. 2000, 393: 123 - 20
Romanelli MN.Gualtieri F. Med. Res. Rev. 2003, 24: 393 - 21
Dwoskin LP.Crooks PA. J. Pharmacol. Exp. Ther. 2001, 298: 395 - 22
Manske RHF. Can. J. Res. 1938, 16: B, 57 - 23
Wonnacott S.Albuquerque EX.Bertrand D. Methods Neurosci. 1993, 12: 263 - 24
Goodson JA. J. Chem. Soc. 1943, 139 - 25
Ulubelen A.Desai HK.Srivastava SK.Hart BP.Park J.-C.Joshi BS.Pelletier SW.Mericli AH.Mericli F.Ilarslan R. J. Nat. Prod. 1996, 59: 360 - 26
Jennings KR.Brown DG.Wright DP. Experientia 1986, 42: 611 - 27
Ward JM.Cockcroft VB.Lunt GG.Smillie FS.Wonnacott S. FEBS Lett. 1990, 270: 45 - 28
Lind RJ.Hardick DJ.Blagbrough IS.Potter BVL.Wolstenholme AJ.Davies ARL.Clough MS.Earley FGP.Reynolds SE.Wonnacott S. Insect Biochem. 2001, 31: 533 - 29
Panter KE.Manners GD.Stegelmeir BL.Lee S.Gardner DR.Ralphs MH.Pfister JA.James LF. Biochem. Syst. Ecol. 2002, 30: 113 - 30
Hardick DJ.Blagbrough IS.Cooper G.Potter BVL.Critchley T.Wonnacott S. J. Med. Chem. 1996, 39: 4860 - 31
Jacyno JM.Harwood JS.Lin N.Campbell JE.Sullivan JP.Holladay MW. J. Nat. Prod. 1996, 59: 707 - 32
Kukel CF.Jennings KR. Can. J. Physiol. Pharmacol. 1994, 72: 104 - 33
Manners GD.Panter KE.Pelletier SW. J. Nat. Prod. 1995, 58: 863 - 34
Manners GD.Panter KE.Pfister JA.Ralphs MH.James LF. J. Nat. Prod. 1998, 61: 1086 - 35
Gardner DR.Manners GD.Panter KE.Lee ST.Pfister JA. J. Nat. Prod. 2000, 63: 1127 - 36
Blagbrough IS.Coates PA.Hardick DJ.Lewis T.Rowan MG.Wonnacott S.Potter BV. Tetrahedron Lett. 1994, 35: 8705 - 37
Coates PA.Blagbrough IS.Hardick DJ.Rowan MG.Wonnacott S.Potter BV. Tetrahedron Lett. 1994, 35: 8701 - 38
Blagbrough IS.Hardick DJ.Wonnacott S.Potter BVL. Tetrahedron Lett. 1994, 35: 3367 - 39
Hardick DJ.Blagbrough IS.Wonnacott S.Potter BVL. Tetrahedron Lett. 1994, 35: 3371 - 40
Pelletier SW.Ross SA. Heterocycles 1990, 31: 671 - 41
Ross SA.Pelletier SW. Heterocycles 1991, 32: 1307 - 42
Davies ARL.Hardick DJ.Blagbrough IS.Potter BVL.Wolstenholme AJ.Wonnacott S. Neuropharmacology 1999, 38: 679 - 43
Hardick DJ.Blagbrough IS.Potter BVL. J. Am. Chem. Soc. 1996, 118: 5897 - 44
Navarro HA.Zhong D.Abraham P.Xu H.Carroll FI. J. Med. Chem. 2000, 43: 142 - 45
Bergmeier SC.Lapinsky DJ.Free RB.McKay DB. Bioorg. Med. Chem. Lett. 1999, 9: 2263 - 46
Byant DL.Free RB.Thomasy SM.Lapinsky DJ.Ismail KA.McKay SB.Bergmeier SC.McKay DB. Neurosci. Res. 2002, 42: 57 - 47
Ismail KA.Bergmeier SC. Eur. J. Med. Chem. 2002, 469 - 48
Doisy X.Blagbrough IS.Wonnacott S.Potter BVL. Pharm. Pharmacol. Commun. 1998, 4: 313 - 49
Simoni D.Rossi M.Rondanin R.Baruchello R.Grisolia G.Eleopra M.Giovannini R.Bozzoli A.Davalli S.Di Fabio R.Donati D. Tetrahedron Lett. 2005, 46: 759 - 50
Coates PA.Blagbrough IS.Rowan MG.Potter BVL.Pearson DPJ.Lewis T. Tetrahedron Lett. 1994, 35: 8709 - 51
Coates PA.Blagbrough IS.Rowan MG.Pearson DPJ.Lewis T.Potter BVL. J. Pharm. Pharmacol. 1996, 48: 210 - 52
Grangier G.Trigg WJ.Lewis T.Rowan MG.Potter BVL.Blagbrough IS. Tetrahedron Lett. 1998, 39: 889 - 53
Trigg WJ.Grangier G.Lewis T.Rowan MG.Potter BVL.Blagbrough IS. Tetrahedron Lett. 1998, 39: 893 - 54
Callis DJ.Thomas NF.Pearson DPJ.Potter BVL. J. Org. Chem. 1996, 61: 4634 - 55
Baillie LC.Bearder JR.Whiting DA. J. Chem. Soc., Chem. Commun. 1994, 2487 - 56
Baillie LC.Batsanov A.Bearder JR.Whiting DA. J. Chem. Soc., Perkin Trans. 1 1998, 3471 - 57
Baillie LC.Bearder JR.Sherringham JA.Whiting DA. J. Chem. Soc., Perkin Trans. 1 1997, 2687 - 58
Baillie LC.Bearder JR.Li W.-S.Sherringham JA.Whiting DA. J. Chem. Soc., Perkin Trans. 1 1998, 4047 - 59
Kraus GA.Dneprovskaia E. Tetrahedron Lett. 1998, 39: 2451 - 60
Kumar P.Dinesh CU.Pandey B. Tetrahedron Lett. 1994, 35: 9229 - 61
Barker D.Brimble MA.McLeod MD. Synthesis 2003, 656 - 62
Barker D.Brimble MA.McLeod MD.Savage GP.Wong DJ. J. Chem. Soc., Perkin Trans. 1 2002, 924 - 63
Barker D.McLeod MD.Brimble MA.Savage GP. Tetrahedron Lett. 2001, 42: 1785 - 64
Barker D.Brimble MA.McLeod MD.Savage GP. Tetrahedron 2004, 60: 5953 - 65
Barker D.McLeod MD.Brimble MA.Savage GP. Tetrahedron Lett. 2002, 43: 6019 - 66
Barker D.Brimble MA.McLeod MD.Savage GP. Org. Biomol. Chem. 2004, 2: 1659 - 67
Brocke C.Brimble MA.Lin DS.-H.McLeod MD. Synlett 2004, 2359 - 68
Davies ARL.Hardick DJ.Blagbrough IS.Potter BVL.Wolstenholme AJ.Wonnacott S. Biochem. Soc. Trans. 1997, 25: 5455 - 69
Kraus GA.Andersh B.Su Q.Shi J. Tetrahedron Lett. 1993, 34: 1741 - 70
Kraus GA.Shi J. J. Org. Chem. 1991, 56: 4147 - 71
Kraus GA.Shi J. J. Org. Chem. 1990, 55: 5423 - 72
Kraus GA.Kesavan S. Tetrahedron Lett. 2005, 46: 1111